共 207 条
[1]
Desnick RJ(2006)Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy Nephrol Ther 2 172-185
[2]
Banikazemi M(1999)Prevalence of lysosomal storage disorders JAMA 281 249-254
[3]
Meikle PJ(2011)Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment JACC Cardiovasc Imaging 4 592-601
[4]
Hopwood JJ(2001)Natural history of Fabry disease in affected males and obligate carrier females J Inherit Metab Dis 24 13-14
[5]
Clague AE(2006)Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomyopathy Am J Cardiol 97 1515-1518
[6]
Carey WF(2003)Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium Eur Heart J 24 2151-2155
[7]
Niemann M(2007)Myocardial late gadolinium enhancement in specific cardiomyopathies by cardiovascular magnetic resonance: a preliminary experience J Cardiovasc Med (Hagerstown) 8 1076-1079
[8]
Herrmann S(2013)Fibrosis: a key feature of Fabry disease with potential therapeutic implications Orphanet J Rare Dis 8 116-97
[9]
Hu K(2004)Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts Mol Genet Metab 82 93-352
[10]
Breunig F(2014)Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: Effectiveness of ERT in different disease stages J Inherit Metab Dis 37 341-645